Vireo Growth Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $209.3 million (+335.1% year over year) and diluted EPS of $0.00. It usually reports 14–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 14–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
209
+335.1%
|
-0
+99.3%
|
0.00
+100.0%
|
|
Apr 14, 2026
14 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
106
+333.5%
|
-20
-212.3%
|
-0.02
+0.0%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
92
+264.2%
|
-26
-433.8%
|
-0.03
-50.0%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
48
+91.6%
|
-15
-2129.2%
|
-0.80
|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
24
+1.7%
|
-6
+3.2%
|
-0.02
+60.0%
|
|
Mar 4, 2025
63 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
25
+3.5%
|
-16
-242.6%
|
-0.07
-110.9%
|
|
Apr 6, 2023
6 days after quarter end
|
—
ended Mar 31, 2023
|
—
|
—
|
—
|
|
Nov 15, 2022
46 days after quarter end
|
—
ended Sep 30, 2022
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VREOF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Minneapolis, MN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1771706
- Former names
- Goodness Growth Holdings, Inc. (until Jun 24, 2024); Vireo Health International, Inc. (until May 14, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.